FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Dextran topics
Recombinant
Recombinant Protein
Ophthalmic
Ascorbic Acid
Polysaccharides
Ethylene Glycol
Hydroquinone
Cultured Cells
Culture Media
Epithelial
Epithelial Cell
Eukaryotic
Fibroblast
Cell Culture Media
Magnetic Field

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Dextran patents



      
           
This page is updated frequently with new Dextran-related patents. Subscribe to the Dextran RSS feed to automatically get the update: related Dextran RSS feeds.

Subscribe to updates on this page: Dextran RSS RSS

Date/App# patent app List of recent Dextran-related patents
04/10/14
20140100111
 Seed coating hydrogels patent thumbnailSeed coating hydrogels
A bio-degradeable seed coating composition for enhanced seed protection and propagation comprises a gelatin-based hydrogel formulation consisting of a naturally derived, hydrophilic protein in combination with a sulfated or non-sulfated polysaccharide. The protein is animal porcine or bovine derived while the polysaccharide is preferably a cellulose derivative such as sodium cellulose sulfate, dextran sulfate, sulfated chitosan, sulfated starch and mixtures thereof.
04/03/14
20140094435
 Use of dextran sulfate patent thumbnailUse of dextran sulfate
A method of inhibiting instant blood-mediated inflammatory reaction (ibmir) in a patient, comprises administering a therapeutically effective amount of dextran sulfate, or a pharmaceutically acceptable salt thereof. A method of inhibiting morphological disruption of a transplanted cell transplant in a patient comprises administering a therapeutically effective amount of dextran sulfate, or a pharmaceutically acceptable salt thereof, to a patient.
04/03/14
20140093484
 Use of dextran sulfate patent thumbnailUse of dextran sulfate
A graft composition intended for transplantation into a patient comprises an injection solution comprising an isolated cell transplant and dextran sulfate, or a pharmaceutically acceptable salt thereof.. .
02/27/14
20140058527
 Cartilage repair mixture containing allograft chondrocytes patent thumbnailCartilage repair mixture containing allograft chondrocytes
The invention is directed toward a sterile cartilage defect implant material comprising milled lyophilized allograft cartilage pieces ranging from 0.01 mm to 1.0 mm in size in a bioabsorbable carrier taken from a group consisting of sodium hyaluronate, hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered pbs, dextran or mixed polymers with allograft chondrocytes added in an amount ranging from 2.5×105 to 2.5×107.. .
02/27/14
20140056818
 Process for delivering encapsulated neutral bioimaging molecules, complex, and process thereof patent thumbnailProcess for delivering encapsulated neutral bioimaging molecules, complex, and process thereof
The present disclosure relates to delivering neutral bioimaging molecules encapsulated within icosahedral dna capsules in vivo and in vitro. The present disclosure also discloses the entrapment of neutral bioimaging molecules like fitc dextran within the cavity of a dna polyhedron without any molecular recognition or chemical conjugation between host (dna icosahedron) and cargo (like fitc dextran).
02/20/14
20140050747
 Trace elements patent thumbnailTrace elements
The invention discloses a trace element solution, which comprises at least one metal selected from the group comprising selenium, copper, zinc, manganese and chromium; and at least one component selected from the group comprising a vitamin, a vaccine, a growth stimulant, a dewormer, iron dextran, an antibiotic and a synchronisation preparation. The synchronisation preparation is a combination of injectable hormonal preparations, inplantable hormonal preparations, intravaginal hormonal preparation and other slow release hormonal preparation.
02/13/14
20140045788
 Method of stably treating incontinence using a bulking agent patent thumbnailMethod of stably treating incontinence using a bulking agent
The invention provides a method for treating fecal incontinence in a subject comprising administering in an appropriate subject a therapeutically effective amount of a biocompatible bulking agent to the wall of the anal canal. The biocompatible bulking agent comprises dextranomer and a pseudoplastic carrier, such as, hyaluronic acid, and is stable and effective in treating fecal incontinence for over 24 months, and up to at least 36 months or more following an initial administration..
02/13/14
20140045787
 Hypertonic dextran solution and methods of treating and preventing recurrent corneal erosion patent thumbnailHypertonic dextran solution and methods of treating and preventing recurrent corneal erosion
An ophthalmic solution is provided. The ophthalmic solution is hypertonic.
02/13/14
20140045786
 Hypertonic dextran solution and methods of treating and preventing recurrent corneal erosion patent thumbnailHypertonic dextran solution and methods of treating and preventing recurrent corneal erosion
An ophthalmic solution is provided. The ophthalmic solution is hypertonic.
01/30/14
20140030303
 Stabilized enzyme compositions patent thumbnailStabilized enzyme compositions
A medical device includes a base material having an immobilized enzyme and dextran sulfate. The dextran sulfate has a molecular weight that is less than 40 kilo dalton (kda).
01/23/14
20140023586
Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
The subject invention relates to the compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran with technetium-99m and for stabilizing the dtpa-dextran cold kit. The composition contains stannous chloride ions to reduce 99mtc-pertechnetate, ascorbic acid to reduce stannic ions to stannous ions to maintain a reducing environment, α,α-trehalose to add bulk and to stabilize the lyophilized composition without interfering with the radiochemical yield, and glycine to transchelate technetium-99m under highly acidic conditions to facilitate radiolabeling dtpa-dextran with high radiochemical purity.
01/09/14
20140010742
Method of increasing the stability of a bayer process liquor
Methods, and related products and compositions, of increasing the stability of a bayer process liquor are described. A method of increasing the stability of a bayer process liquor includes contacting the bayer process liquor with a ppm quantity of a low molecular weight dextran.
01/02/14
20140005379
Nanoparticle delivery system and components thereof
The present disclosure relates generally to a nanoparticle delivery system. The nanoparticles are formed from amphiphilic block copolymers comprising polylactide and dextran.
01/02/14
20140005142
Method of stably treating incontinence using a bulking agent
The invention provides a method for treating fecal incontinence in a subject comprising administering in an appropriate subject a therapeutically effective amount of a biocompatible bulking agent to the wall of the anal canal. The biocompatible bulking agent comprises dextranomer and a pseudoplastic carrier, such as, hyaluronic acid, and is stable and effective in treating fecal incontinence for over 24 months, and up to at least 36 months or more following an initial administration..
12/26/13
20130344518
Method for measuring cholesterol in hdl subfraction, and reagents and kit therefor
The present invention provides a method for simply and precisely measuring cholesterol in an hdl subfraction contained in a sample. This is a method for measuring cholesterol in hdl3 contained in a sample, which comprises reacting a sample with (1) a combination of a cholesterol ester hydrolase and a cholesterol oxidase or (2) a combination of a cholesterol ester hydrolase, an oxidized coenzyme and a cholesterol dehydrogenase in an aqueous medium containing: (a) a divalent metal salt; (b) an alkali metal salt selected from the group consisting of a sulfate, a nitrate, a carbonate, an acetate and a halide; and (c) dextran sulfate or a salt thereof, and measuring a substance formed or consumed in the reaction without separating and removing lipoproteins other than hdl3..
12/05/13
20130323182
Method of preparing iron oxide nanoparticles coated with hydrophilic material, and magnetic resonance imaging contrast agent using the same
The present invention relates to a method of preparing biocompatible iron oxide nanoparticles by coating iron oxide nanoparticles having improved magnetism via annealing treatment using salt particles with a hydrophilic material and to a magnetic resonance imaging (mri) contrast agent including the iron oxide nanoparticles prepared thereby. Among hydrophilic materials, carboxymethyl dextran (cm-dextran) is the most efficient in terms of stabilizing the annealed iron oxide nanoparticles and exhibiting contrast effects..
11/28/13
20130316977
Priming solutions for cardiopulmonary bypass
The present invention relates to priming solutions used during cardiopulmonary bypass procedures. In particular, the present invention relates to a cardiopulmonary bypass priming solution comprising a balanced salt solution and a combination of oncotic and non-oncotic dextran molecules.
11/28/13
20130315839
Iron oxide nanoparticles as mri contrast agents and their preparing method
Iron oxide nano contrast agents for magnetic resonance imaging which have superior t2 contrast effect, and also can be used as a storage or a carrier for drugs and so on, are disclosed. The iron oxide nano contrast agents can be prepared by the steps of: coating surfaces of hydrophobic feo nanoparticles with a coating material selected from the group consisting of polyethylene glycol-phospholipid conjugate, dextran, chitosan, dimercaptosuccinic acid and mixtures thereof in an organic solvent to form hydrophilic feo nanoparticles having hydrophilic surfaces and dispersibility in water; dispersing the hydrophilic feo nanoparticles in water to oxidize feo; and exposing the oxidized hydrophilic feo nanoparticles to an acidic buffer to dissolve and remove interior unoxidized feo portions, and thereby to form fe3o4 nanoparticles having an interior space..
11/14/13
20130303983
Coated medical devices including a water-insoluble therapeutic agent
A medical device includes an implantable structure and a coating layer including a water-insoluble therapeutic agent and one or more additives selected from heparin, heparan sulfate, dextran and dextran sulfate, and physiologically-acceptable salts thereof. The one or more additives can be present in an amount effective to increase the rate of release of the water-insoluble therapeutic agent from the coating layer.
11/07/13
20130296285
Design of hydrolytically releasable prodrugs for sustained release nanoparticle formulations
A prodrug according to formula (i) wherein r2 is a residue of a drug, said drug having a hydroxyl group by which the coor2 group is formed; z is o or nh; m is 0 or 1; and r3 is an organic moiety comprising a lipophilic group or a residue of a polymer, provided that z is 0 if the polymer is carboxymethyl dextran. A system includes a plurality of magnetic nanoparticles including a prodrug as described above, a stent and a source of uniform magnetic field capable of producing temporary magnetization of the stent and/or the magnetic nanoparticles.
11/07/13
20130295667
Serum-free mammalian cell culture medium, and uses thereof
The present invention provides a cell culture medium formulation that supports the in vitro cultivation, particularly in suspension, of mammalian cells, particularly epithelial cells and fibroblast cells, and methods for cultivating mammalian cells in suspension in vitro using these media. The media comprise a basal medium and a polyanionic or polyanionic compound, preferably a polysulfonated or polysulfated compound, and more preferably dextran sulfate.
10/24/13
20130280321
Method of inducing hemostasis in a wound
A method of inducing hemostasis in a wound using a hemostatic product. A dextran support is provided.
09/26/13
20130253555
Ophthalmic surgical method comprising a step of at least partly removing the vitreous humour
An ophthalmic surgical method comprising a step of at least partly removing the vitreous humour, which also comprises a step of highlighting the vitreous to be removed using a coloured composition which selectively highlights the vitreous, allowing a distinction between the vitreous and the other structures of the eye, said distinction facilitating vitreous removal, wherein the coloured composition comprises a polymeric dye comprising at least one backbone to which at least one reactive dye is chemically linked; in a preferred embodiment the polymeric dye being a blue dextran.. .
09/19/13
20130245549
Bioresorable drug delivery matrices based on cross-linked polysaccharides, dosage forms designed for delayed/controlled release
Bioactive agents are embedded in a cross-linked dextran and coated with a bioresorbable polymer. When implanted in a mammal, the coated cross-linked dextran composition produces controlled release of the embedded bioactive agent..
09/19/13
20130244978
Ophthalmic composition
The present invention provides an ophthalmic composition which stabilizes the tear film during wearing contact lens, prevents eye dryness, imparts a favorable sensation in using, is highly convenient with no risk of misuse and shows a high efficiency in the course from manufacturing to sales. More specifically, the present invention provides a wetting solution—eye drops for contact lenses or an ophthalmic composition/solution for contact lenses, which comprises (a) one or more member(s) selected from the group consisting of a cellulose-based polymer, a vinyl-based polymer, polyethylene glycol and dextran; and (b) a terpenoid..
09/19/13
20130244974
Surgical hydrogel
A composition suitable for use in wound healing, particularly for reducing post-surgical adhesions, containing cross-linked derivatives of chitosan and dextran polymers. A hydrogel forms when solutions of the polymers are combined..
08/22/13
20130217867
Recombinant production of heparin binding proteins
A process for recovering and purifying refolded heparin binding proteins produced in heterologous host cells includes the step of incubation of the solubilized protein with a polyanionic species such as dextran sulfate.. .
08/01/13
20130195739
Cross-linked ethylsulfonated dihydroxypropyl cellulose
The invention provides methods and compositions for improving the production of alumina hydrate. The invention involves adding one or more cross-linked ethylsulfonated polysaccharides to liquor or slurry in the fluid circuit of the production process.
06/27/13
20130165771
Use of fitc-dextran as dye for fundus angiography and methods thereof
A novel fundus angiographic application and method using fluorescein isothiocyanate dextrans (fitc-dextran) as fluorescence angiographic dye for diagnosis and evaluation of eye diseases on humans is disclosed. The method involves the process of constitution of fitc-dextran solution and intravenous injection of the said solution, followed by observation and photography of ocular fundus circulation using a fluorescence fundus camera with an image system.
06/20/13
20130157974
Preparation comprising iron(iii) complex compounds and redox-active substance(s)
A preparation is disclosed that comprises one or more iron(iii) complex compounds which have a redox potential at ph 7 of from −324 mv to −750 mv relative to a normal hydrogen electrode (nhe), and one or more redox-active substances, wherein the carbohydrates are selected from the group consisting of dextrans and hydrogenated dextrans, dextrins, oxidised or hydrogenated dextrins, as well as pullulan, oligomers thereof and/or hydrogenated pullulans, and wherein the redox-active substance(s) is/are selected from the group consisting of ascorbic acid; vitamin e; cysteine; physiologically acceptable phenols/polyphenols selected from the group consisting of quercetin, rutin, flavones, flavonoids, hydroquinones; and glutathione, and in particular is ascorbic acid.. .
05/23/13
20130130969
Antimicrobial peptide, branched forms thereof and their use in the treatment of bacteria infections
The instant invention refers to an antibacterial peptide with all aminoacids in d-configuration, possessing strong antimicrobial activity against gram-negative and gram-positive bacteria and candida strains. The peptide can be in linear form or multimerised on a skeleton of polyacrylamide, of dextrane units or on a skeleton of ethylene glycol units.
05/16/13
20130121929
Polyol and polyether iron oxide complexes as pharmacological and/or mri contrast agents
Iron oxide complexes, pharmacological compositions and unit dosage thereof, and methods for their administration, of the type employing an iron oxide complex with a polyol, are disclosed. The pharmacological compositions employ a polysaccharide iron oxide complex, wherein the polysaccharide is a modified polyol such as a carboxyalkylated reduced dextran.
05/09/13
20130115200
Cell therapy
Dextran sulfate is used in order to reduce pulmonary uptake of intravenously injected dextran sulfate is capable of reducing the pulmonary uptake of the intravenously injected cells to the levels obtained for intraarterial injection of the cells but without the accompanying risks and side effects of using intraarterial cell injection. The dextran sulfate can therefore be used in a composition together with tumor infiltrating t-lymphocytes to treat metastatic cancer in a subject..
05/02/13
20130109633
Cb-183,315 compositions and related methods
The present disclosure provides novel solid cb-183,315 formulations which have improved chemical stability. The chemical stability of the solid cb-183,315 is dependent on the process by which the composition is made.
04/25/13
20130102977
Ophthalmic composition
The present invention provides an ophthalmic composition which stabilizes the tear film during wearing contact lens, prevents eye dryness, imparts a favorable sensation in using, is highly convenient with no risk of misuse and shows a high efficiency in the course from manufacturing to sales. More specifically, the present invention provides a wetting solution—eye drops for contact lenses comprising (a) one or more member(s) selected from the group consisting of a cellulose-based polymer, a vinyl-based polymer, polyethylene glycol and dextran; and (b) a terpenoid..
04/25/13
20130102730
Polyamine-containing polymers and methods of synthesis and use
The present invention relates to polyamine-containing polymers and methods of their synthesis and use. The polymer may be hydroxyethylcellulose, dextran, poly(vinyl alcohol) or poly(methyl acrylate)..
04/25/13
20130102561
Stabalized glycosaminoglycan preparations and related methods
Compositions comprising a glycosaminoglycan (e.g., a hyaluronan, hyaluronic acid, hyaluronate, sodium hyaluronate, dermatan sulfate, karatan sulfate, chondroitin 6-sulfate, heparin, etc.) in combination with at least one component selected from; i) polyglycols (e.g., polyethylene glycol), ii) long chain hydroxy polyanionic polysaccharides (e.g., dextran, sodium alginate, alginic acid, propylene glycol alginate, carboxymethyl cellulose and carboxyethyl cellulose, hydroxyl ethyl starch, hydroxyl propyl methyl cellulose, hydroxy propyl ethyl cellulose, hydroxy propyl cellulose, methyl cellulose, polylysine, polyhistidine, polyhydroxy proline, poly ornithine, polyvinyl pyrolidone, polyvinyl alcohol, chitosan, etc.) and iii) long chain nitrogen containing polymers (e.g., polylysine, polyvinylpyrrolidone, and polyvinyl alcohol). The invention also includes methods for using such compositions (e.g., as substance delivery materials, tissue fillers or bulking agents, as moistening or hydrating agents, etc.).
04/25/13
20130102079
Polyamine-containing polymers and methods of synthesis and use
The present invention relates to polyamine-containing polymers and methods of their synthesis and use. The polymer may be hydroxyethylcellulose, dextran, poly(vinyl alcohol) or poly(methyl acrylate)..
04/25/13
20130101507
Treatment of renal cell carcinoma
Methods for treating renal cancer by administration of certain 3,3′,4,4′-tetrahydroxy-2,2′-bipyridine-n,n′-dioxide compounds, especially 3,3′,4,4′-tetrahydroxy-2,2′-bipyridine-n,n′-dioxide (orellanine), conjugated to an alpha-emitting radionuclide (e.g. Astatine-211) to increase the efficacy of the formulation and/or a large molecule (e.g.
04/18/13
20130096479
Method of forming hemostatic products
A hemostatic product having a plurality of hemostatic layers. Each of the hemostatic layers includes a dextran support and at least one hemostatic agent, which is selected from the group consisting of thrombin and fibrinogen.
04/18/13
20130095229
Method of forming dextran and thrombin sheets
A method of forming hemostatic sheets. Dextran and water are mixed to form a dextran-water mixture.
04/18/13
20130095165
Stabilizers for hemostatic products
A hemostatic product that includes a dextran support, at least one hemostatic agent and at least one hemostatic agent stabilizer. The at least one hemostatic agent is selected from the group consisting of thrombin and fibrinogen.
03/28/13
20130079301
Hypertonic dextran solution and methods of treating and preventing recurrent corneal erosion
An ophthalmic solution is provided. The ophthalmic solution is hypertonic.
03/14/13
20130065826
Injectable solution at ph 7 comprising at least one basal insulin whose pi is between 5.8 and 8.5
A composition in the form of an injectable aqueous solution, the ph of which is between 6.0 and 8.0, includes at least a basal insulin, the isoelectric point pi of which is between 5.8 and 8.5; and a dextran substituted by radicals carrying carboxylate charges and hydrophobic radicals. Single-dose formulations at a ph of between 7 and 7.8 includes a basal insulin whose isoelectric point is between 5.8 and 8.5 and a prandial insulin..
03/14/13
20130065275
Serum-free mammalian cell culture medium, and uses thereof
The present invention provides a cell culture medium formulation that supports the in vitro cultivation, particularly in suspension, of mammalian cells, particularly epithelial cells and fibroblast cells, and methods for cultivating mammalian cells in suspension in vitro using these media. The media comprise a basal medium and a polyanionic or polyanionic compound, preferably a polysulfonated or polysulfated compound, and more preferably dextran sulfate.
03/14/13
20130065218
Medical fluid, a method of treatment and use of the fluid
A medical fluid for a harvested organ, tissue or parts thereof, for evaluation and/or preservation. The fluid includes cocaine or a stimulating analogue thereof; nor-adrenalin; and/or adrenaline.
03/07/13
20130058847
Methods to improve filtration for the bayer process
The invention provides methods and compositions for improving the production of alumina trihydrate. The invention involves adding one or more cross-linked polysaccharides to a filter used to separate solids from liquid in the bayer process.
02/28/13
20130053453
Dermal filler composition
The present invention relates to a novel dermal filler composition and a method for preparing the same. Even though the composition of the present invention comprises, as a main component, only cross-linked dextran having the molecular weight of 30,000 to 100,000, the composition can rapidly augment a detective area of the skin and maintain softness to the touch even, the composition eliminates the necessity of a pretreatment, such as an allergy test, which might otherwise be required prior to injection, is inexpensive, and is not easily decomposed or absorbed in vivo, thereby stably maintaining the tissue-volume augmentation effects after injection over a long period of time..
02/28/13
20130052300
Fat replacers and filling materials
The present invention relates generally to fat replacers and their use in various food products. Aspects of the disclosure are particularly directed to oligodextran-based fat replacers that are lower in calories, heat stable, and increase fiber.
02/07/13
20130035309
Ophthalmic sealant composition and method for use
A polymeric hydrogel sealant specifically formulated to seal ophthalmic wounds is provided. The sealant is formed by mixing two aqueous solutions.
01/10/13
20130011826
Methods and kits for decreasing interferences from leukocytes in specific binding assays
The present disclosure describes methods and kits for reducing interferences in immunoassays performed on solid phase and on samples containing serum or plasma, by adding an effective amount of a polycationic derivative of dextran to the assay.. .


Popular terms: [SEARCH]

Dextran topics: Recombinant, Recombinant Protein, Ophthalmic, Ascorbic Acid, Polysaccharides, Ethylene Glycol, Hydroquinone, Cultured Cells, Culture Media, Epithelial, Epithelial Cell, Eukaryotic, Fibroblast, Cell Culture Media, Magnetic Field

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patents related to Dextran for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Dextran with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.2516

2326

1 - 1 - 54